Welcome to our dedicated page for Gilead Sciences SEC filings (Ticker: GILD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gilead Sciences, Inc. (Nasdaq: GILD) is a Delaware‑incorporated biopharmaceutical company whose common stock is registered on The Nasdaq Global Select Market. As an SEC‑reporting issuer, Gilead files a range of regulatory documents that provide detailed insight into its financial condition, governance and material events. This page aggregates GILD’s SEC filings and pairs them with AI‑generated summaries to help readers understand the key points in complex disclosures.
For Gilead, Form 10‑K annual reports and Form 10‑Q quarterly reports are central sources of information on its HIV, viral hepatitis, COVID‑19, oncology and inflammation businesses, including segment discussions, risk factors and research and development spending. Form 8‑K current reports capture specific developments such as quarterly financial results, amendments to bylaws, executive leadership changes and significant agreements. Recent 8‑K filings, for example, have disclosed financial results for particular quarters, updates to the company’s bylaws governing director nominations and stockholder proposals, patent settlements related to Biktarvy, and changes in senior corporate affairs and legal roles.
Investors can also use this page to access proxy statements for information on board structure and executive compensation, and Form 4 insider transaction reports to track trades by directors and officers. Because Gilead is not classified as an emerging growth company, its filings follow the full disclosure requirements applicable to large, established issuers.
Stock Titan enhances GILD filings with AI‑powered explanations that highlight material items, translate technical accounting and legal language into plain terms, and surface topics such as governance changes, litigation updates or collaboration agreements. Real‑time ingestion from EDGAR means new Gilead filings appear quickly, while the AI layer helps readers focus on what changed, why it matters for the company’s HIV, antiviral and oncology franchises, and how it may affect shareholders.
Form 144 filing for Gilead Sciences (GILD) reports proposed and recent insider sales of common stock by Daniel O'Day. The filing shows an intended sale of 10,000 shares through Morgan Stanley Smith Barney on NASDAQ with an aggregate market value of $1,136,300 and an approximate sale date of 08/28/2025. The shares were originally acquired as restricted stock on 03/01/2022. The filer also reported three recent sales by the same person: 10,000 shares on 07/28/2025 for $1,139,369, 10,000 shares on 06/30/2025 for $1,104,483, and 10,000 shares on 05/30/2025 for $1,104,192. The filing lists 1,240,806,916 shares outstanding.
Johanna Mercier, Chief Commercial Officer of Gilead Sciences (GILD), reported multiple transactions on 08/15/2025 executed under a Rule 10b5-1 trading plan adopted Feb 20, 2025. The filing shows a series of option-related acquisitions and open-market sales in common stock: total reported sales on that date equal 28,000 shares at prices ranging roughly from $117.91 to $119.01, and multiple option exercises/acquisitions at an exercise price of $66.64. Following the reported transactions, the filing lists beneficial ownership levels of common stock as low as 114,168 shares and various counts of options/derivatives remaining outstanding. The Form 4 also discloses that the related options have a four-year vesting schedule with 25% vesting after one year and the remainder vesting quarterly thereafter.
Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences (GILD), reported an insider sale on Form 4. The filing shows a sale of 2,500 shares of Gilead common stock on 08/15/2025 at a price of $118.53 per share, leaving Mr. Dickinson with 160,110 shares beneficially owned after the transaction. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on 08/29/2024. The Form 4 was signed by Edward S. Son by power of attorney for Mr. Dickinson and dated 08/18/2025.
Form 144 filing for Gilead Sciences (GILD) shows an insider intends to sell 2,500 common shares through Morgan Stanley Smith Barney on 08/15/2025, with an aggregate market value of $296,325 and the shares listed for sale on NASDAQ. The filing identifies prior acquisitions of the shares as restricted stock granted on 03/10/2024 (1,200 shares) and 03/10/2023 (1,300 shares). The notice also lists sales by the same person during the past three months totaling 5,000 shares with aggregate cash proceeds of approximately $553,000. The filer signs a representation that they are not aware of undisclosed material adverse information about the issuer.
Gilead Sciences insider notice for proposed Rule 144 sale. The filing reports a proposed sale of 28,000 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $3,318,924.65 and the company’s outstanding shares listed as 1,240,806,916. The filer shows recent acquisitions including a 25,000-share stock option exercise dated 08/15/2025, 2,394 performance shares (01/31/2024) and 606 restricted shares (12/10/2023). The form also lists multiple dispositions by Johanna Mercier in the past three months, with individual sales and gross proceeds disclosed for each trade.
FAQ
What is the current stock price of Gilead Sciences (GILD)?
What is the market cap of Gilead Sciences (GILD)?
